Medtronic, Titan Spine, Thermo Fisher Scientific, Fujifilm, Bayer, GlaxoSmithKline, Eli Lilly, Merck, Braun, Au Jiabao, Alibaba Medical, Hansen Pharmaceutical , CStone Pharmaceutical, Jinxin Fertility, Wantai Biological and other companies for a weekImportant news review.
Medtronic completed the acquisition of Titan Spine
Medtronic recently completed the acquisition of Titan Spine . Titan Spine is a privately-owned titanium spinal implant and surface technology company. Prior to this, the two companies announced the final acquisition agreement on May 9, 2019. This transaction strengthens Medtronic's position as a leading innovator of spinal surgery procedures. Titan Spine pioneered and led the field of surface-enhanced titanium implants with its unique nano-lock body platform. Titan Spine joins Medtronic's spine department as part of the recovery treatment group. It is expected that this transaction acquisition will not matter to Medtronic's adjusted earnings per share for fiscal year 2020, and is expected to meet Medtronic's long-term acquisition financial indicators.
Thermo Fisher completes the sale of anatomical pathology business
The world’s leading scientific service company Thermo Fisher THermo Fisher Scientific Inc. announced that it has completed the previously announced sale of its anatomical pathology business to PHC Holdings for $1.14 billion in cash. PHC Holdings is a leading global healthcare company that provides innovative solutions. The anatomical pathology business has approximately 1,200 employees in the United States. The company’s annual revenue in the United States, Europe and Asia is approximately US$350 million and is part of Thermo Fisher’s professional diagnostics division.
Thermo Fisher is the world's leading scientific service company with annual revenue of more than 24 billion U.S. dollars and approximately 70,000 employees worldwide.
Fujifilm and Bayer will develop new iPS cancer immune drugsstrong>
Japan’s Fujifilm Holdings announced that it has joined hands with the German pharmaceutical company Bayer to begin research and development of cancer immune drugs using iPS cells. Drugs using iPS cells have not yet been put into practical use in the world. In this context, the two companies will use third-party iPS cells other than patients to advance the development. The previous iPS cell cancer immunity drugs in Japan cost tens of millions of yen each time and are expensive, but they use the methods of these two companies , The cost may fall.
Fujifilm subsidiary and Versant Venture Management LLC, a US venture fund with advantages in the healthcare fieldThe established American company received capital from Bayer. The proportion of each company’s investment is not disclosed, but Fujifilm regards US companies as companies subject to the equity method. The development cost is estimated to be 250 million U.S. dollars, and Bayer will bear nearly 90%.
U.S. pharmaceutical companies begin a new round of price increases
U.S. pharmaceutical companies begin to The new round of price increases involves injectable generic drugs administered by hospitals that are in short supply.
Braun B. Braun MedicalInc. raises prices for the most types of drugs. The company has raised the prices of more than a dozen drugs, many of which are used in hospitals. B. Braun increased the price of the antibiotic cefazolin by 50% to more than $9 per pack. According to the US Food and Drug Administration (FDA), cefazolin, which has been around for decades, is currently facing a shortage of supply like several other antibiotics. According to Rx Savings Solutions, overall, 20 pharmaceutical companies increased the catalog prices of more than 40 prescription drugs by an average of 13.1%. Rx Savings Solutions sells software that helps employees and health insurance plans choose the cheapest drugs. On July 1st last year, 16 pharmaceutical companies increased the catalog prices of dozens of drugs by an average of 7.8%.
The global wearable medical device market is expected to exceed US$87 billion
According to Global Market Insights, Inc. A new research report released. The increase in physical health awareness and the increase in consumer disposable income will become the main driving factors for the growth of the wearable medical device market. The global wearable medical device market will achieve a compound annual growth rate of 39% from 2019 to 2025. By 2025, the global wearableDai's medical equipment market is expected to exceed $87 billion. During the forecast period, high spending on wearable device marketing will have a positive impact on business growth. Increasing spending on the development of smart phone-based medical applications in developing countries will also have a positive impact on market growth. However, data security issues related to these devices may limit the expansion of the industry to a certain extent in the next few years.
In 2018, the fitness monitoring part of the wearable medical device market accounted for more than 25% of the market share, and the diabetes care monitoring application field accounted for more than 20% of the market share. Health monitoring equipment is used to monitor health-related indicators, such as calorie consumption, walking distance, and in some cases, sleep and heartbeat. Based on applications, the industry is subdivided into heart health, obesity control, diabetes care, health monitoring, sleep tracking, etc.
The technical review of the first domestic HPV vaccine is basically completed
The two prices jointly declared by Xiamen Wantai Canghai, Xiamen University and Wantai Biotechnology The technical review of the HPV vaccine has been basically completed and is currently waiting for on-site verification. According to the vaccine’s marketing process, after the on-site verification and the three batches of inspections, the drug regulatory department will conduct a three-in-one comprehensive evaluation and consider it safe , Effective, authentic, and controllable quality vaccines will be issued to companies for production approval. If successfully approved for marketing, this bivalent HPV vaccine will alsoIt will be the first domestic cervical cancer vaccine to be marketed in China. China will become the third country after the United States and the United Kingdom to have the ability to independently supply cervical cancer vaccines.
Alibaba AI overcomes difficult cardiovascular recognition technology
Alibaba announces that it has achieved in the field of medical AI New development: Conquered cardiovascular recognition technology with a higher degree of difficulty. "Learning to count After 100,000 training samples, Ali AI does not require manual interaction. It only takes 0.5 seconds to extract a single coronary artery, and it takes no more than 20 to extract a complete coronary tree. Second, the efficiency is nearly a hundred times higher than that of traditional methods,” said the relevant person in charge of Ali AI.
In recent years, the visual computing team of Ali Dharma Academy has repeatedly made major breakthroughs in the field of medical AI. In 2018, Ali's AI technology for diagnosing liver nodules won two world firsts, and is currently continuing to study whether it can judge liver cancer.p>8
Hong Kong has become a popular IPO destination for Chinese pharmaceutical companies
Data compiled by Bloomberg shows that In half a year, Chinese overseas IPOs were cold in the first quarter and recovered in the second quarter. Most of the top ten Chinese overseas IPOs in the first half of the year were completed in the second quarter. Judging from the listing locations of the top ten transactions, Hong Kong is still Chinese-funded Popular destinations for IPOs. The top ten overseas IPOs of Chinese companies in the first half of 2019 are: Huatai Securities, Shenwan Hongyuan, Hansen Pharmaceutical, Ruixing Coffee, China Oriental Education, Xinyi Energy, Jinxin Fertility, CStone Pharmaceuticals, Haitong Hengxin and China Ship Leasing.
Among them, medical pharmaceutical companies occupies three seats: Hansen Pharmaceuticals has raised net funds of 7HK$6.4 billion (approximately USD 1 billion), listed on June 14, 2019. CStone Pharmaceuticals raised HK$2.232 billion (approximately USD 287 million), 2019 It was listed on February 26, 2010. Jinxin Fertility raised HK$3.05 billion (approximately US$389 million) to be listed on June 25, 2019.
Many pharmaceutical companies' new drugs have been approved or listed in China
GlaxoSmithKline’s new asthma and chronic obstructive pulmonary drug Wan Ruishu was launched in China. GSK China announced that its new ICS/LABA drug Valesul (generic name: fluticasone furoate/vilanterol, FF/VI) officially entered the Chinese market. As the only one by one once-a-day ICS/LABA drug currently on the market, Valerix helps to improve slow breathing Disease management.
Mersk’s new in vitro deworming drug for dogs was launched in China. Mersk Animal Health announced its oral antiparasitic drug for dogsFlerelana chewable tablets are on the market in China for the treatment of flea and tick infections on the surface of dogs, and can also assist in the treatment of allergic dermatitis caused by fleas. As a chewable tablet against flea and tick infection that provides long-term protection for dogs for 12 weeks, this product only needs to be administered once every 12 weeks.
Lilly’s new rheumatoid arthritis drug was approved in China. Lilly China announced that the National Medical Products Administration (NMPA) has approved ailemin (baritinib tablets) 2mg tablets for the treatment of moderate to severe active rheumatoid arthritis in adults. Ailemin (Baritinib tablets) is a tyrosine protein kinase (JAK) 1/2 inhibitor, administered orally once a day.
A major personnel affairs have occurred at Bayer and Aojiabo Changes
Since July 1, 2019, Jiang Wei will take over as Bayer’s senior country representative in Greater China. Currently Bayer’s senior country representative in Greater China Zhu Lixian has decided to leave Bayer to seek other career development opportunities. After taking over, Jiang Wei will continue to serve as the President of Bayer's Prescription Drugs Division in China and as the Executive Vice President of Bayer's Prescription Drugs Division and the President of China and Asia Pacific. Report.
Australia’s leading natural nutrition company BLACKMORES announced its appointmentOrder Mr. Alastair Symington as the global CEO and managing director. The appointment will take effect on October 1, 2019. Currently, Minteng Shi is the senior vice president of Coty Beauty Consumer Products, responsible for the business of this large consumer products manufacturer and retailer in Asia, Latin America, the Middle East, Africa and Australia.
"Pharmaceutical Health News" daily releases the latest business trends, financial report information, mergers and acquisitions, and personnel appointments and removals of global pharmaceutical, medical, and health companies. It is timelyA good channel to understand the development trends of global pharmaceutical and health companies and industries.